Teva Pharmaceutical Industries Limited (NYSE:TEVA) Short Interest Update

Teva Pharmaceutical Industries Limited (NYSE:TEVA) saw a significant decline in short interest in October. As of October 15th, there was short interest totalling 19,910,000 shares, a decline of 18.7% from the September 30th total of 24,490,000 shares. Based on an average daily trading volume, of 7,430,000 shares, the short-interest ratio is currently 2.7 days.

Teva Pharmaceutical Industries Trading Up 0.8 %

Shares of NYSE:TEVA traded up $0.16 during trading on Wednesday, reaching $18.59. 6,343,361 shares of the company were exchanged, compared to its average volume of 9,307,149. The business’s fifty day simple moving average is $18.02 and its 200-day simple moving average is $16.87. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59. Teva Pharmaceutical Industries has a 12-month low of $8.42 and a 12-month high of $19.08. The firm has a market capitalization of $21.05 billion, a PE ratio of -45.33, a P/E/G ratio of 1.29 and a beta of 0.88.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The business had revenue of $4.16 billion during the quarter, compared to analyst estimates of $3.99 billion. On average, research analysts anticipate that Teva Pharmaceutical Industries will post 2.33 EPS for the current year.

Insider Buying and Selling

In related news, insider Eric A. Hughes sold 24,537 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the transaction, the insider now directly owns 45,060 shares of the company’s stock, valued at approximately $777,285. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.55% of the stock is owned by company insiders.

Institutional Trading of Teva Pharmaceutical Industries

A number of hedge funds have recently added to or reduced their stakes in the business. Sequoia Financial Advisors LLC boosted its position in Teva Pharmaceutical Industries by 0.7% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock valued at $2,025,000 after acquiring an additional 805 shares in the last quarter. Edmond DE Rothschild Holding S.A. boosted its stake in Teva Pharmaceutical Industries by 4.0% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 24,495 shares of the company’s stock valued at $346,000 after acquiring an additional 947 shares in the last quarter. Signaturefd LLC grew its holdings in Teva Pharmaceutical Industries by 16.9% in the third quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock worth $137,000 after purchasing an additional 1,094 shares during the last quarter. Oppenheimer & Co. Inc. increased its position in shares of Teva Pharmaceutical Industries by 9.6% during the first quarter. Oppenheimer & Co. Inc. now owns 13,522 shares of the company’s stock worth $191,000 after purchasing an additional 1,180 shares in the last quarter. Finally, QRG Capital Management Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 0.8% during the 2nd quarter. QRG Capital Management Inc. now owns 144,938 shares of the company’s stock valued at $2,355,000 after purchasing an additional 1,191 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on TEVA shares. UBS Group raised their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research report on Wednesday, July 10th. JPMorgan Chase & Co. boosted their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Finally, Barclays upped their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.